Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:BCAX NASDAQ:EOLS NASDAQ:ETNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$7.80-0.4%$7.64$5.47▼$11.99$181.30M-0.2370,091 shs196,560 shsBCAXBicara Therapeutics$18.68-0.7%$12.94$7.80▼$28.09$1.02BN/A583,027 shs800,780 shsEOLSEvolus$6.30-4.7%$6.74$5.71▼$17.49$407.52M1.041.08 million shs834,304 shsETNB89BIO$14.77-0.2%$11.26$4.16▼$15.06$2.19B1.272.84 million shs2.00 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-3.21%+11.70%+11.86%+25.08%-5.66%BCAXBicara Therapeutics+8.67%+4.50%+65.29%+61.46%-5.95%EOLSEvolus+3.77%+6.44%-0.30%-29.23%-60.42%ETNB89BIO+0.07%-0.07%+84.54%+38.97%+84.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$7.80-0.4%$7.64$5.47▼$11.99$181.30M-0.2370,091 shs196,560 shsBCAXBicara Therapeutics$18.68-0.7%$12.94$7.80▼$28.09$1.02BN/A583,027 shs800,780 shsEOLSEvolus$6.30-4.7%$6.74$5.71▼$17.49$407.52M1.041.08 million shs834,304 shsETNB89BIO$14.77-0.2%$11.26$4.16▼$15.06$2.19B1.272.84 million shs2.00 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-3.21%+11.70%+11.86%+25.08%-5.66%BCAXBicara Therapeutics+8.67%+4.50%+65.29%+61.46%-5.95%EOLSEvolus+3.77%+6.44%-0.30%-29.23%-60.42%ETNB89BIO+0.07%-0.07%+84.54%+38.97%+84.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 2.50Moderate Buy$20.33164.24% UpsideBCAXBicara Therapeutics 2.75Moderate Buy$31.8671.28% UpsideEOLSEvolus 2.40Hold$21.25239.19% UpsideETNB89BIO 2.40Hold$25.8174.82% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, ETNB, EOLS, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025BCAXBicara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025EOLSEvolusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ACTUActuate TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ACTUActuate TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BCAXBicara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025EOLSEvolusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/23/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/19/2025ETNB89BIORaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Market Perform9/19/2025ETNB89BIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.50(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.01 per shareN/ABCAXBicara TherapeuticsN/AN/AN/AN/A$9.04 per shareN/AEOLSEvolus$277.94M1.46N/AN/A$0.09 per share69.61ETNB89BION/AN/AN/AN/A$3.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$27.28MN/A0.00∞N/AN/AN/A-281.83%N/ABCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)EOLSEvolus-$50.42M-$0.98N/AN/AN/A-22.31%-759.04%-24.63%11/5/2025 (Estimated)ETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)Latest ACTU, ETNB, EOLS, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025BCAXBicara Therapeutics-$0.55N/AN/AN/AN/AN/A11/6/2025Q3 2025ETNB89BIO-$0.50N/AN/AN/AN/AN/A11/5/2025Q3 2025EOLSEvolus-$0.14N/AN/AN/A$67.75 millionN/A8/14/2025Q2 2025ACTUActuate Therapeutics-$0.19-$0.30-$0.11-$0.30N/AN/A8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A0.730.73BCAXBicara TherapeuticsN/A25.8025.80EOLSEvolusN/A2.271.86ETNB89BIO0.0715.1915.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ABCAXBicara TherapeuticsN/AEOLSEvolus90.69%ETNB89BION/AInsider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%BCAXBicara Therapeutics15.50%EOLSEvolus5.90%ETNB89BIO2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1023.24 million7.13 millionN/ABCAXBicara Therapeutics3254.61 million46.15 millionN/AEOLSEvolus17064.69 million60.87 millionOptionableETNB89BIO40148.31 million144.45 millionOptionableACTU, ETNB, EOLS, and BCAX HeadlinesRecent News About These CompaniesStockWatch: Novo Nordisk Raises MASH Bet with Up-to-$5.2B Akero AcquisitionOctober 13 at 12:47 AM | genengnews.comG89BIO (NASDAQ:ETNB) Sees Unusually-High Trading Volume - Here's What HappenedOctober 11, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for 89BIO (NASDAQ:ETNB)October 8, 2025 | marketbeat.com89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNBOctober 6, 2025 | businesswire.com89BIO (NASDAQ:ETNB) Given Average Rating of "Moderate Buy" by BrokeragesOctober 3, 2025 | marketbeat.comAssessing 89bio (ETNB) Valuation Following a 60% Share Price RallyOctober 2, 2025 | finance.yahoo.com89BIO Sees Unusually High Options Volume (NASDAQ:ETNB)October 2, 2025 | marketbeat.com89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout DealSeptember 30, 2025 | msn.com89BIO $ETNB Shares Acquired by Voya Investment Management LLCSeptember 25, 2025 | marketbeat.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)September 23, 2025 | prnewswire.comAssenagon Asset Management S.A. Has $21.32 Million Stock Position in 89BIO $ETNBSeptember 23, 2025 | marketbeat.comRBC Capital Reaffirms Their Hold Rating on 89bio (ETNB)September 22, 2025 | theglobeandmail.comRhumbline Advisers Has $1.11 Million Holdings in 89BIO $ETNBSeptember 21, 2025 | marketbeat.com89BIO (NASDAQ:ETNB) Sees Strong Trading Volume - Still a Buy?September 20, 2025 | marketbeat.comHC Wainwright Reaffirms Neutral Rating for 89BIO (NASDAQ:ETNB)September 20, 2025 | marketbeat.com89BIO (NASDAQ:ETNB) Receives Peer Perform Rating from Wolfe ResearchSeptember 20, 2025 | marketbeat.comWolfe Research Downgrades 89bio (ETNB)September 19, 2025 | msn.com89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNBSeptember 19, 2025 | businesswire.com89BIO (NASDAQ:ETNB) Hits New 52-Week High - Time to Buy?September 19, 2025 | marketbeat.comRaymond James cuts 89bio to “market perform” after Roche’s $14.50 per share dealSeptember 19, 2025 | finance.yahoo.com89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche MergerSeptember 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Intel + NVIDIA: The Unexpected AI Alliance Shaking Wall StreetBy Jeffrey Neal Johnson | September 25, 2025Industrial Tech Crossovers: When Manufacturing Meets InnovationBy Nathan Reiff | September 23, 2025Eli Lilly’s Oral GLP-1 Breakthrough Could Change EverythingBy Chris Markoch | September 18, 2025ACTU, ETNB, EOLS, and BCAX Company DescriptionsActuate Therapeutics NASDAQ:ACTU$7.80 -0.03 (-0.38%) Closing price 04:00 PM EasternExtended Trading$7.80 +0.00 (+0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Bicara Therapeutics NASDAQ:BCAX$18.68 -0.13 (-0.69%) Closing price 04:00 PM EasternExtended Trading$18.65 -0.03 (-0.16%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Evolus NASDAQ:EOLS$6.30 -0.31 (-4.69%) Closing price 04:00 PM EasternExtended Trading$6.25 -0.05 (-0.79%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.89BIO NASDAQ:ETNB$14.77 -0.03 (-0.20%) Closing price 04:00 PM EasternExtended Trading$14.77 0.00 (0.00%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
